© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
A clinical trial has confirmed that new HIV treatment Trogarzo suppresses one’s viral load.
The Conference on Retroviruses and Opportunistic Infections in Seattle saw many important studies that are advancing the fight against HIV.
Researchers followed a small group of people with highly drug-resistant virus taking injectable antibody.
Researchers gave the antibody treatment to those with multidrug-resistant HIV along with an optimized antiretroviral regimen.
Nelson Vergel pushes for the development of new salvage therapies.
The Food and Drug Administration approves antibody treatment Trogarzo for multidrug-resistant HIV.
The intravenous medication, which should be used with standard antiretrovirals, has a wholesale acquisition cost of $118,000 per year.
With an FDA decision for ibalizumab pending, data about a group with multidrug resistance show that the antibody is effective.
TaiMed Biologics has applied for approval of the weekly injectable antibody ibalizumab for people with multidrug-resistant virus.
TaiMed Biologics has applied for approval of the weekly injectable antibody ibalizumab for those with multidrug-resistant virus.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
